***Background.*** Isavuconazole (ISA) is a novel, broad-spectrum, triazole antifungal available as a water-soluble prodrug in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial (NCT00412893) assessed the efficacy and safety of ISA vs voriconazole (VRC) in patients with invasive mold disease (IMD). Neutropenia is linked to significant morbidity and mortality in patients with IMD. We present outcomes in patients with and without neutropenia at baseline from this trial.

***Methods.*** Patients with proven/probable/possible IMD (EORTC/MSG criteria) were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, then 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. The primary endpoint was all-cause mortality through Day 42. Overall success at end-of-treatment (EOT) as determined by an independent data-review committee (DRC), safety, and tolerability were also analyzed. Neutropenia was defined as per EORTC/MSG criteria.

***Results.*** Patient characteristics, efficacy, and safety outcomes are shown in the table.

***Conclusion.*** ISA has comparable efficacy to VRC for the primary treatment of IMD in neutropenic and non-neutropenic patients and may be better tolerated.

###### 

Patient characteristics and outcomes

                                   Neutropenic   Non-neutropenic                                                             
  ------------------------------- ------------- ----------------- ---------------------------------- ----------- ----------- ----------------------------------
  All treated patients (ITT), n        163             175                        94                     84                  
  Proven/probable IMD (mITT), n        88              73                         55                     56                  
  *Efficacy*                                                                                                                 
                                    ISA n (%)       VRC n (%)      Adjusted difference\* % (95% CI)   ISA n (%)   VRC n (%)   Adjusted difference\* % (95% CI)
  All-cause mortality Day 42                                                                                                 
   ITT                               34 (21)         37 (21)              --0.2 (--8.7, 8.3)           14 (15)     15 (18)          --4.0 (--14.2, 6.2)
   mITT                              22 (25)         17 (23)              2.4 (--10.2, 14.9)           6 (11)      13 (23)         --13.5 (--26.8, --0.3)
  Overall success EOT                                                                                                        
   ITT                               67 (41)         75 (43)              2.2 (--8.3, 12.8)            24 (25)     23 (28)           1.0 (--13.2, 15.2)
   mITT                              34 (39)         29 (40)              0.4 (--14.0, 14.7)           16 (29)     18 (32)           2.5 (--13.3, 18.2)
  *Safety*                                                                                                                   
  AEs, n (%)                                                                                                                 
   ITT                              158 (97)        172 (98)                   89 (95)                 83 (99)               
   mITT                              85 (97)         71 (97)                   53 (96)                 55 (98)               
  Drug-related AEs, n (%)                                                                                                    
   ITT                               70 (43)        101 (58)                   39 (42)                 54 (64)               
   mITT                              35 (40)         41 (56)                   22 (40)                 38 (68)               

\*ISA--VRC (VRC--ISA for overall success)

ITT, intent-to-treat population (patients who received ≥1 dose of study drug); mITT, modified intent-to-treat population (patients in ITT with proven/probable IMD as assessed by DRC)
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